Related Experiment Videos

Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with

I-Te Lee1, Wayne Huey-Herng Sheu, Shih-Yi Lin

  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan, ROC.

Journal of Diabetes and Its Complications
|December 13, 2002
PubMed

Insights

Simvastatin significantly reduced high-sensitivity C-reactive protein (hs-CRP) levels in type 2 diabetic patients with hyperlipidemia. This suggests statin therapy may help manage inflammation and reduce coronary heart disease risk in this population.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • High-sensitivity C-reactive protein (hs-CRP) is linked to coronary artery disease prevalence.
  • HMG-CoA reductase inhibitors (statins) reduce hs-CRP and recurrent coronary events.
  • Type 2 diabetes increases coronary heart disease mortality risk, potentially via inflammation.

Purpose of the Study:

  • To evaluate the effect of simvastatin on plasma hs-CRP levels in type 2 diabetic patients with hyperlipidemia.

Main Methods:

  • Prospective study involving 17 type 2 diabetic patients with hyperlipidemia on a lipid-lowering diet.
  • 14 patients completed 8 weeks of simvastatin 20 mg daily.
  • Fasting blood samples were collected pre- and post-treatment.

Main Results:

  • Simvastatin significantly decreased hs-CRP from 0.312±0.057 to 0.193±0.045 mg/dL (P<.01).
  • Plasma LDL cholesterol also significantly reduced from 130±9 to 74±3 mg/dL (P=.001).

Conclusions:

  • Eight-week simvastatin administration effectively reduces plasma hs-CRP concentrations in type 2 diabetic patients with hyperlipidemia.
  • Simvastatin demonstrates potential in managing inflammatory markers associated with cardiovascular risk in this patient group.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
579
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571